For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

CVS Health, the parent of PBM juggernaut CVS Caremark, won’t presently add Gilead’s twice-yearly pre-exposure prophylaxis drug Yeztugo to its commercial plans or Affordable Care Act formularies, a company spokesperson confirmed to Fierce Pharma.